Adam Steensberg, Zealand Pharma CEO (Betty Laura Zapata/Bloomberg via Getty Images)
September 9, 2024 11:45 AM EDT
R&D

Zealand’s GLP-1/GLP-2 drug bounces back with new Phase 1b da­ta

Ayisha Sharma

News Reporter

Zealand Phar­ma’s GLP-1/GLP-2 re­cep­tor dual ag­o­nist showed promis­ing weight loss in an ear­ly-stage tri­al af­ter a pre­vi­ous ef­fort with low­er dos­es end­ed with “un­der­whelm­ing” ef­fi­ca­cy …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

In sur­prise, study sug­gests Covid mR­NA vac­cines may boost can­cer im­munother­a­py ef­fi­ca­cy

Mer­ck­'s Eli­av Barr on sub­cu­ta­neous Keytru­da, Sum­mit and deal shop­ping

FDA tells on­col­o­gy com­pa­nies how to run mul­ti-re­gion­al can­cer tri­als with a US ap­proval in mind

Pfiz­er tees up Phase 3 test in weight man­age­ment — but in an un­ex­pect­ed area

Boehringer plans NDA fil­ing for pul­monary fi­bro­sis drug fol­low­ing Phase 3 da­ta

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times